Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

1.1 This document describes the funding and supply arrangements for inclisiran (Leqvio®) as an option in the lipid management pathway. These arrangements follow from the recommendations NICE set out ...

To ensure that a full range of lipid management treatments is available, we have renegotiated an agreement with Novartis for continued access to inclisiran, maintaining the same price for current and ...

There is no easy way to unclog an artery once plaque has built up. However, dietary choices, exercise, and avoiding smoking can improve cardiovascular health and stop blockages from worsening.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration ...

College of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular ...

Treatment of familial hypercholesterolemia is directed toward the moment of the medical encounter. However, risk for heart disease as a consequence of having familial hypercholesterolemia is related ...

The condition is “high-risk” plaque, once narrowly defined as plaque built up in the arteries that is likely to rupture, possibly leading to an acute heart attack or sudden cardiac death.

Inclisiran, a siRNA that targets proprotein convertase subtilisin/kexin Type 9(PCSK9), shows significant promise as an effective therapy for lowering LDL cholesterol levels, particularly in patients ...